SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

InvestSource, Inc.: ACTCellerate Technology Licensed to BioTime, Inc by Advanced Cell Technology
[August 12, 2008]

InvestSource, Inc.: ACTCellerate Technology Licensed to BioTime, Inc by Advanced Cell Technology


(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:12082008

Stocks in the news: Advanced Cell Technology, Inc. (OTC: ACTC), Altus
Pharmaceuticals Inc. (NASDAQ: ALTU), OMRIX Biopharmaceuticals, Inc.
(NASDAQ: OMRI), Health Discovery Corporation (OTCBB: HDVY)

August 11, 2008 -- Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC)
announced today that it has granted an exclusive license to Embryome
Sciences, Inc., a wholly owned subsidiary of BioTime, Inc., to use
"ACTCellerate" embryonic stem cell technology and a bank of over 140
diverse progenitor cell lines derived using that technology. Under the
agreement, ACT received an upfront payment of $250,000, and is eligible
to receive an 8% royalty on sales of products, services, and processes
that utilize the licensed technology. Once a total of $1,000,000 of
royalties has been paid, no further royalties will be due. ACT has an
option to reacquire rights to use the ACTCellerate technology for the
development of certain types of stem cells for human therapeutic use in
fields related to its core business.

ACTCellerate is a recently discovered technology that allows the rapid
isolation of novel highly purified embryonic progenitor cells.
Embryonic progenitors are cells intermediate between embryonic stem
cells and fully differentiated cells. The progenitor cells are
relatively easy to manufacture on a large scale and in a purified
state, which may make it advantageous to work with these cells compared
to the direct use of embryonic stem cells. Using the ACTCellerate
platform technology over 140 distinguishable novel progenitor cell
lines have already been created, scaled-up, and banked. These unique
cell lines may possess the ability to become a wide array of products
never before available to the medical community, with potential
applications in research, drug discovery, and human regenerative stem
cell therapy.

"We are pleased that we were able to enter into an agreement to
monetize non-core technologies," said William M. Caldwell, IV, ACT's
Chairman and CEO. "We continue to seek potential licensees and joint
venture partners to share in the development costs of many of our
promising clinical programs."

Additional information about ACTCellerate technology appears in the May
2008 edition of the journal Regenerative Medicine
(www.futuremedicine.com/toc/rme/3/3). ACTCellerate is a trademark of
Advanced Cell Technology, Inc.

August 11, 2008 -- Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announces
its Phase 3 efficacy trial of TrizytekTM (porcine-free enzymes) in
patients with cystic fibrosis (CF) successfully met its primary
endpoint of improvement in fat absorption. The Company released results
from its 163 patient, double-blind, placebo-controlled trial of
Trizytek, an enzyme replacement therapy for patients with pancreatic
insufficiency. Trizytek is a stable and pure combination of three
active enzymes in a fixed-ratio that is designed to improve fat,
protein and carbohydrate absorption in pancreatic insufficient
individuals. Altus' Trizytek Phase 3 clinical program is the largest
ever conducted to evaluate the efficacy and safety of pancreatic enzyme
replacement therapy in cystic fibrosis patients. Detailed trial results
will be presented at the North American Cystic Fibrosis Conference in
October 2008.

In cystic fibrosis patients with exocrine pancreatic insufficiency,
Trizytek demonstrated a statistically significant improvement of fat
absorption over placebo through the measurement of the coefficient of
fat absorption (CFA). The primary efficacy analysis was an intent to
treat (ITT) analysis in the sub-group of patients with severe
malabsorption (baseline CFA below 40). In addition, data were analyzed
for the overall group.

Patients treated with Trizytek had a statistically significant
improvement in CFA compared to placebo. In the Trizytek CFA<40 group,
there was an improvement in the mean CFA of 20.2 (80% change from
baseline). In the placebo CFA<40 group, there was an increase in mean
CFA of 5.1 (24% change from baseline). The mean difference between
groups for the change in CFA was 15.1 (p=0.001).

August 11, 2008 -- OMRIX Biopharmaceuticals, Inc. ("Omrix") (NASDAQ:
OMRI), a fully-integrated biopharmaceutical company that develops and
markets biosurgical and immunotherapy products, announced today the
appointment of Asaf Alperovitz, as Chief Financial Officer (CFO)
effective October 23, 2008.

Mr. Alperovitz has been CFO from 2005 of Tefron LTD, a multinational
manufacturing company listed on both the New York (NYSE: TFR) and
Tel-Aviv (TASE: TFRN) Stock Exchanges. From 2003 until 2005, Mr.
Alperovitz was CFO of Corigin Ltd., an international enterprise
software company. Prior to 2003, Mr. Alperovitz held a variety of
management positions with Ernst & Young in Israel and the United
States. His client-base included publicly traded companies in the U.S.,
Europe and Israel and his experience includes mergers and acquisitions
as well as equity and debt public offerings.

In his position as CFO of Omrix, Mr. Alperovitz will be responsible for
finance, strategic, operational and financial planning, investor
relations and information technology systems.

Mr. Alperovitz is a Certified Public Accountant and holds a Bachelor's
degree in Accounting and Economics and a Masters in Business
Administration from Tel-Aviv University.

August 11, 2008 -- Health Discovery Corporation ("HDC") (OTCBB: HDVY)
today announced that HDC's new gene-based molecular diagnostic test for
prostate cancer which has now successfully completed its Phase III
double-blind clinical trial and is now ready for commercialization,
will be presented at the upcoming Biomarker Discovery Europe 2008
conference in Dublin, Ireland on October 2-3. The new prostate cancer
test will be performed at Clarient's Clinical Laboratory in Aliso
Viejo, CA. HDC will receive 30% royalty on each test performed.

CEO of Health Discovery Corporation, was invited to participate as a
Distinguished Presenter on the Faculty of the Biomarker Discovery
Europe 2008 Summit.

Dr. Barnhill will present the results from Phase I, Phase II and Phase
III double-blind clinical validation studies now completed with
prostate tissues obtained from multiple sites, including those tested
in collaboration with MD Anderson Cancer Center which demonstrated a
very high success rate for identifying the presence of Grade 3 or



higher prostate cancer cells (clinically significant cancer), as well
as, normal and BPH (benign prostatic hyperplasia) cells. His
presentation will emphasize that to date, 322 prostate tissues have
been tested - and that the combined results of the recently completed
double-blind clinical validation studies demonstrated on the new
gene-based molecular diagnostic test for prostate cancer achieved a
Sensitivity of 90% for correctly identifying the presence of Grade 3 or
higher prostate cancer cells, and a Specificity of 97% for correctly
identifying non-cancer cells (normal and BPH), representing an overall
test accuracy of 93%.

Market Wrap for August 11, 2008 - The stock market posted a solid gain
on Monday, with notable strength in financials and retailers.


The financial sector ended the day with a gain of 1.7%, a substantial
retreat from its session high when it was up as much 3.8%.

Consumer discretionary (+2.5%) stocks were an area of strength.
Retailing stocks posted a solid advance of 4.8%, after being up as much
as 8.0%. Amazon.com (AMZN 88.05, +7.54) soared 9.4% after Citi said
that sales of Amazon's electronic book reader, Kindle, appear to be
much stronger than expected.

The energy sector (-0.4%) was a laggard, with a steep drop in coal
stocks (-5.2%) acting as a major drag. The materials sector (-0.4%)
also posted a loss. Mining stocks came under pressure after gold
(-3.8%) and silver (-4.4%) prices tumbled as the dollar rose 0.5%.

In corporate news, Waste Management (WMI 36.09, +0.08) raised its offer
to purchase Republic Services (RSG 35.05, +0.19) to $37 per share, or
$6.73 billion, from $34 per share.

Food products company Sysco (SYY 31.11, +1.24) said its latest
quarterly earnings rose 12% year-over-year to $0.55 per share, which
topped Wall Street's forecast of $0.52.

Small-cap stocks outperformed, with the Russell 2000 Index climbing
2.3%. This, along with strength in AMZN, helped the Nasdaq Composite
(+1.1%) outpace the Dow (+0.4%) and S&P 500, which only contain
large-cap stocks.DJ30 +48.03 NASDAQ +25.85 NQ100 +0.8% R2K +2.3% SP400
+0.9% SP500 +9.00 NASDAQ Adv/Vol/Dec 1993/2.30 bln/857 NYSE Adv/Vol/Dec
1955/1.26 bln/1158

ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO
TO: www.investsourceinc.com.

Coming in late Summer of this year: Go Baby GO!!! The first book of its
kind on the OTCBB and Pink Sheet Markets
www.gobabygobook.com .

To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to
www.ceo-corner.com InvestSource, Inc. is not a licensed broker, broker
dealer, market maker, investment banker, investment advisor, analyst or
underwriter. InvestSource, Inc. affiliates, officers, directors and
employees may also have bought, or may buy the shares discussed in this
opinion and may profit in the event of a rise in value. InvestSource,
Inc. will not advise as to when it decides to sell and does not, and
will not, offer any opinion as to when others should buy or sell; each
investor must make that decision based on his or her judgment of the
market InvestSource has received 5 million shares of Greenstone
Holdings for services rendered. Please consult your broker before
purchasing or selling any securities mentioned herein. To view full
disclaimers, please go to http://investsourceinc.com/php/disclaimer.php
(disclaimers).

This release may contain statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E the Securities Exchange Act of 1934,
as amended. The words "may," "would," "will," "expect," "estimate,"
"anticipate," "believe," "intend," and similar expressions and
variations thereof are intended to identify forward-looking statements.
Investors are cautioned that any such forward-looking statements are
not guarantees of future performance and involve risks and
uncertainties, many of which are beyond the Company's ability to
control, and that actual results may differ materially from those
projected in the forward-looking statements as a result of various
factors. The information contained in an InvestSource profile is
provided as an information service only. The accuracy or completeness
of the information is not warranted and is only as reliable as the
sources from which it was obtained.

CONTACT: InvestSource, Inc
e-mail: info@investsourceinc.com
WWW: http://www.investsourceinc.com

((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).

Copyright ? 2008 M2 Communications Ltd.

[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy